Affinity Asset Advisors’s Regenxbio RGNX Stock Holding History

Affinity Asset Advisors’s Portfolio RGNX Stock Details RGNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-110,000	Closed	-$2.32M	–	119
2024 Q1	$2.32M	Buy	+110,000	New	+$1.96M	0.29%	71

Other funds holding RGNX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

IHAM

Integral Health Asset Management New York $2.09B AUM 112.84% 1-Year Est. Return

Affinity Asset Advisors's RGNX Position: Q2 2024 in Review

Affinity Asset Advisors sold out of Regenxbio (RGNX) in Q2 2024, closing a stake of 110,000 shares — an estimated $2.32M sold.

Affinity Asset Advisors first reported a position in RGNX in Q1 2024 and held it in 1 quarter. The position peaked at $2.32M in Q1 2024. 181 funds tracked by Wall St. Rank hold RGNX as of Q2 2024.

Affinity Asset Advisors reported no remaining Regenxbio position as of Q2 2024 after selling out during the quarter.
Affinity Asset Advisors sold 110,000 Regenxbio shares in Q2 2024, an estimated $2.32M.
Affinity Asset Advisors first reported a position in Regenxbio in Q1 2024 and held it in 1 quarter.
Affinity Asset Advisors's Regenxbio position peaked at $2.32M in Q1 2024.
181 funds tracked by Wall St. Rank held Regenxbio as of Q2 2024.

Based on Affinity Asset Advisors's 13F filing for Q2 2024, filed 14 Aug 2024.